Aviva Valuation
Is GU81 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GU81 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GU81 (€5.85) is trading below our estimate of fair value (€13.64)
Significantly Below Fair Value: GU81 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GU81?
Key metric: As GU81 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is GU81's PE Ratio? | |
|---|---|
| PE Ratio | 10.1x |
| Earnings | UK£1.27b |
| Market Cap | UK£12.90b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.1x |
| Enterprise Value/EBITDA | 1.1x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does GU81's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.5x | ||
TLX Talanx | 10.9x | 5.0% | €20.6b |
ALV Allianz | 11.9x | 5.9% | €112.5b |
NBG6 NÜRNBERGER Beteiligungs-AG | 14.1x | 38.4% | €587.5m |
HNR1 Hannover Rück | 13.2x | 5.7% | €29.8b |
GU81 Aviva | 10.1x | 4.2% | €12.9b |
Price-To-Earnings vs Peers: GU81 is good value based on its Price-To-Earnings Ratio (10.1x) compared to the peer average (12.5x).
Price to Earnings Ratio vs Industry
How does GU81's PE Ratio compare vs other companies in the European Insurance Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: GU81 is good value based on its Price-To-Earnings Ratio (10.1x) compared to the European Insurance industry average (11.8x).
Price to Earnings Ratio vs Fair Ratio
What is GU81's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 10.1x |
| Fair PE Ratio | 9.7x |
Price-To-Earnings vs Fair Ratio: GU81 is expensive based on its Price-To-Earnings Ratio (10.1x) compared to the estimated Fair Price-To-Earnings Ratio (9.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €5.85 | €6.51 +11.3% | 6.1% | €7.06 | €5.57 | n/a | 15 |
| Nov ’25 | €5.40 | €6.47 +19.8% | 6.3% | €7.08 | €5.58 | n/a | 15 |
| Oct ’25 | €5.85 | €6.46 +10.5% | 6.2% | €7.01 | €5.70 | n/a | 16 |
| Sep ’25 | €6.10 | €6.36 +4.3% | 6.5% | €6.95 | €5.66 | n/a | 15 |
| Aug ’25 | €5.90 | €6.28 +6.5% | 7.4% | €6.94 | €5.17 | n/a | 15 |
| Jul ’25 | €5.70 | €6.09 +6.9% | 7.1% | €6.88 | €5.30 | n/a | 15 |
| Jun ’25 | €5.60 | €6.02 +7.4% | 8.5% | €6.86 | €4.93 | n/a | 15 |
| May ’25 | €5.55 | €5.90 +6.3% | 8.6% | €6.71 | €4.90 | n/a | 15 |
| Apr ’25 | €5.85 | €5.90 +0.8% | 8.6% | €6.71 | €4.90 | n/a | 15 |
| Mar ’25 | €5.20 | €5.77 +10.9% | 6.8% | €6.73 | €5.21 | n/a | 15 |
| Feb ’25 | €5.05 | €5.76 +14.0% | 6.9% | €6.74 | €5.22 | n/a | 15 |
| Jan ’25 | €5.05 | €5.64 +11.6% | 6.6% | €6.36 | €4.92 | n/a | 15 |
| Dec ’24 | €4.84 | €5.63 +16.3% | 6.9% | €6.37 | €4.93 | n/a | 15 |
| Nov ’24 | €4.64 | €5.55 +19.6% | 7.4% | €6.26 | €4.67 | €5.40 | 15 |
| Oct ’24 | €4.60 | €5.49 +19.4% | 8.0% | €6.25 | €4.68 | €5.85 | 15 |
| Sep ’24 | €4.38 | €5.57 +27.2% | 7.9% | €6.37 | €4.78 | €6.10 | 15 |
| Aug ’24 | €4.68 | €5.68 +21.3% | 9.4% | €6.53 | €4.88 | €5.90 | 16 |
| Jul ’24 | €4.66 | €5.80 +24.5% | 8.1% | €6.52 | €4.89 | €5.70 | 17 |
| Jun ’24 | €4.62 | €5.74 +24.3% | 8.1% | €6.44 | €4.83 | €5.60 | 17 |
| May ’24 | €4.72 | €5.68 +20.4% | 7.4% | €6.19 | €4.76 | €5.55 | 17 |
| Apr ’24 | €4.61 | €5.68 +23.3% | 7.4% | €6.19 | €4.76 | €5.85 | 17 |
| Mar ’24 | €5.16 | €5.64 +9.3% | 8.5% | €6.37 | €4.83 | €5.20 | 18 |
| Feb ’24 | €5.12 | €5.64 +10.1% | 8.9% | €6.35 | €4.79 | €5.05 | 18 |
| Jan ’24 | €4.99 | €5.68 +13.9% | 9.3% | €6.48 | €4.58 | €5.05 | 18 |
| Dec ’23 | €5.12 | €5.77 +12.7% | 9.4% | €6.56 | €4.65 | €4.84 | 17 |
| Nov ’23 | €4.84 | €5.66 +16.9% | 9.2% | €6.50 | €4.61 | €4.64 | 19 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Grupo Catalana Occidente
€4.3b
Provides insurance products and services worldwide.
OCZA
€35.85
7D
-1.6%
1Y
17.2%
Arch Capital Group
US$37.4b
Provides insurance, reinsurance, and mortgage insurance products worldwide.
RSK
US$93.42
7D
-0.05%
1Y
19.0%
Sagicor Financial
CA$872.8m
Provides insurance products and related financial services in Jamaica, Barbados, Trinidad, Tobago, other Caribbean region, and the United States.
3RQ
CA$4.22
7D
7.1%
1Y
7.1%